IPO
Nineteen companies went public during the year, with two offerings nabbing proceeds of more than $1 billion and two more above $500 million.Â
Bluejay Diagnostics Prices $21.6M IPO
The firm anticipates using the net proceeds from the offering for general corporate purposes and to support the development and marketing of its IL-6 Sepsis Triage test.
German MDx Firm Mainz Biomed Raises $10M in IPO, Begins Trading on Nasdaq
The company, which has been developing a colorectal cancer diagnostic called ColoAlert, priced its IPO last week, offering 2 million shares at $5 per share.
MDxHealth Prices IPO of American Depositary Shares
The diagnostics company is offering 3.75 million ADSs at $12 per share and is hoping to raise gross proceeds of $45 million.
Lucid Diagnostics Prices $70M IPO, Starts Trading on Nasdaq
Lucid markets an esophageal DNA test and cell collection device for the detection of gastroesophageal reflux disease, and esophageal precancer and cancer.